FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995652213> ?p ?o ?g. }

• W1995652213 endingPage "1111" @default.
• W1995652213 startingPage "1100" @default.
• W1995652213 abstract "Background & AimsAberrant chromatin modification is a key feature of hepatocellular carcinoma (HCC), which is characterized by strong sexual dimorphism. Both enhancer of zeste homolog 2 (EZH2) and cell cycle-related kinase (CCRK) contribute to hepatocarcinogenesis, yet whether the two oncogenic factors have functional crosstalk is unknown.MethodsCellular proliferation and tumorigenicity upon transgenic expression and RNA interference were determined by colony formation and soft agar assays, xenograft, orthotopic and diethylnitrosamine-induced HCC models. Gene regulation was assessed by chromatin immunoprecipitation, site-directed mutagenesis, luciferase reporter, co-immunoprecipitation and expression analyses. Protein levels in clinical specimens were correlated with clinicopathological parameters and patient survival rates.ResultsEctopic CCRK expression in immortalized human liver cells increased EZH2 and histone H3 lysine 27 trimethylation (H3K27me3) to stimulate proliferation and tumor formation. Conversely, knockdown of CCRK reduced EZH2/H3K27me3 levels and decreased HCC cell growth, which could be rescued by EZH2 over-expression. Mechanistically, GSK-3β phosphorylation by CCRK activated a β-catenin/TCF/E2F1/EZH2 transcriptional feedback loop to epigenetically enhance androgen receptor (AR) signaling. Simultaneously, the phosphorylation of AKT/EZH2 by CCRK facilitated the co-occupancy of CCRK promoter by EZH2-AR and its subsequent transcriptional activation, thus forming a self-reinforcing circuitry. Lentiviral-mediated knockdown of CCRK, which abrogated the phosphorylation-transcriptional network, prevented diethylnitrosamine-induced tumorigenicity. More importantly, the hyperactivation of the CCRK-EZH2 circuitry in human HCCs correlated with tumor recurrence and poor survival.ConclusionsThese findings uncover an epigenetic vicious cycle in hepatocarcinogenesis that operates through reciprocal regulation of CCRK and EZH2, providing novel therapeutic strategy for HCC. Aberrant chromatin modification is a key feature of hepatocellular carcinoma (HCC), which is characterized by strong sexual dimorphism. Both enhancer of zeste homolog 2 (EZH2) and cell cycle-related kinase (CCRK) contribute to hepatocarcinogenesis, yet whether the two oncogenic factors have functional crosstalk is unknown. Cellular proliferation and tumorigenicity upon transgenic expression and RNA interference were determined by colony formation and soft agar assays, xenograft, orthotopic and diethylnitrosamine-induced HCC models. Gene regulation was assessed by chromatin immunoprecipitation, site-directed mutagenesis, luciferase reporter, co-immunoprecipitation and expression analyses. Protein levels in clinical specimens were correlated with clinicopathological parameters and patient survival rates. Ectopic CCRK expression in immortalized human liver cells increased EZH2 and histone H3 lysine 27 trimethylation (H3K27me3) to stimulate proliferation and tumor formation. Conversely, knockdown of CCRK reduced EZH2/H3K27me3 levels and decreased HCC cell growth, which could be rescued by EZH2 over-expression. Mechanistically, GSK-3β phosphorylation by CCRK activated a β-catenin/TCF/E2F1/EZH2 transcriptional feedback loop to epigenetically enhance androgen receptor (AR) signaling. Simultaneously, the phosphorylation of AKT/EZH2 by CCRK facilitated the co-occupancy of CCRK promoter by EZH2-AR and its subsequent transcriptional activation, thus forming a self-reinforcing circuitry. Lentiviral-mediated knockdown of CCRK, which abrogated the phosphorylation-transcriptional network, prevented diethylnitrosamine-induced tumorigenicity. More importantly, the hyperactivation of the CCRK-EZH2 circuitry in human HCCs correlated with tumor recurrence and poor survival. These findings uncover an epigenetic vicious cycle in hepatocarcinogenesis that operates through reciprocal regulation of CCRK and EZH2, providing novel therapeutic strategy for HCC." @default.
• W1995652213 created "2016-06-24" @default.
• W1995652213 creator A5008000310 @default.
• W1995652213 creator A5009718905 @default.
• W1995652213 creator A5024082848 @default.
• W1995652213 creator A5033563425 @default.
• W1995652213 creator A5049274840 @default.
• W1995652213 creator A5050867791 @default.
• W1995652213 creator A5051141598 @default.
• W1995652213 creator A5051223797 @default.
• W1995652213 creator A5055538725 @default.
• W1995652213 creator A5059071043 @default.
• W1995652213 creator A5062076895 @default.
• W1995652213 creator A5067333447 @default.
• W1995652213 creator A5068651440 @default.
• W1995652213 date "2015-05-01" @default.
• W1995652213 modified "2023-10-18" @default.
• W1995652213 title "A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients" @default.
• W1995652213 cites W1974342793 @default.
• W1995652213 cites W1980330982 @default.
• W1995652213 cites W1980937575 @default.
• W1995652213 cites W1990376085 @default.
• W1995652213 cites W1992314595 @default.
• W1995652213 cites W2000307707 @default.
• W1995652213 cites W2014533420 @default.
• W1995652213 cites W2016896762 @default.
• W1995652213 cites W2039845199 @default.
• W1995652213 cites W2044433401 @default.
• W1995652213 cites W2045115988 @default.
• W1995652213 cites W2046150599 @default.
• W1995652213 cites W2052609775 @default.
• W1995652213 cites W2053116646 @default.
• W1995652213 cites W2060608189 @default.
• W1995652213 cites W2062322247 @default.
• W1995652213 cites W2066462676 @default.
• W1995652213 cites W2077804275 @default.
• W1995652213 cites W2077986225 @default.
• W1995652213 cites W2090757807 @default.
• W1995652213 cites W2119754956 @default.
• W1995652213 cites W2123218517 @default.
• W1995652213 cites W2125479243 @default.
• W1995652213 cites W2129501325 @default.
• W1995652213 cites W2132241298 @default.
• W1995652213 cites W2133370909 @default.
• W1995652213 cites W2136415416 @default.
• W1995652213 cites W2137122561 @default.
• W1995652213 cites W2152310279 @default.
• W1995652213 cites W2152701723 @default.
• W1995652213 cites W2160689782 @default.
• W1995652213 cites W2171439874 @default.
• W1995652213 cites W43271413 @default.
• W1995652213 doi "https://doi.org/10.1016/j.jhep.2014.11.040" @default.
• W1995652213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25500144" @default.
• W1995652213 hasPublicationYear "2015" @default.
• W1995652213 type Work @default.
• W1995652213 sameAs 1995652213 @default.
• W1995652213 citedByCount "56" @default.
• W1995652213 countsByYear W19956522132015 @default.
• W1995652213 countsByYear W19956522132016 @default.
• W1995652213 countsByYear W19956522132017 @default.
• W1995652213 countsByYear W19956522132018 @default.
• W1995652213 countsByYear W19956522132019 @default.
• W1995652213 countsByYear W19956522132020 @default.
• W1995652213 countsByYear W19956522132021 @default.
• W1995652213 countsByYear W19956522132022 @default.
• W1995652213 countsByYear W19956522132023 @default.
• W1995652213 crossrefType "journal-article" @default.
• W1995652213 hasAuthorship W1995652213A5008000310 @default.
• W1995652213 hasAuthorship W1995652213A5009718905 @default.
• W1995652213 hasAuthorship W1995652213A5024082848 @default.
• W1995652213 hasAuthorship W1995652213A5033563425 @default.
• W1995652213 hasAuthorship W1995652213A5049274840 @default.
• W1995652213 hasAuthorship W1995652213A5050867791 @default.
• W1995652213 hasAuthorship W1995652213A5051141598 @default.
• W1995652213 hasAuthorship W1995652213A5051223797 @default.
• W1995652213 hasAuthorship W1995652213A5055538725 @default.
• W1995652213 hasAuthorship W1995652213A5059071043 @default.
• W1995652213 hasAuthorship W1995652213A5062076895 @default.
• W1995652213 hasAuthorship W1995652213A5067333447 @default.
• W1995652213 hasAuthorship W1995652213A5068651440 @default.
• W1995652213 hasBestOaLocation W19956522131 @default.
• W1995652213 hasConcept C101762097 @default.
• W1995652213 hasConcept C104317684 @default.
• W1995652213 hasConcept C121608353 @default.
• W1995652213 hasConcept C134320426 @default.
• W1995652213 hasConcept C150194340 @default.
• W1995652213 hasConcept C173396325 @default.
• W1995652213 hasConcept C190232843 @default.
• W1995652213 hasConcept C41091548 @default.
• W1995652213 hasConcept C50171091 @default.
• W1995652213 hasConcept C502942594 @default.
• W1995652213 hasConcept C54355233 @default.
• W1995652213 hasConcept C555283112 @default.
• W1995652213 hasConcept C81885089 @default.
• W1995652213 hasConcept C83640560 @default.
• W1995652213 hasConcept C86803240 @default.
• W1995652213 hasConceptScore W1995652213C101762097 @default.
• W1995652213 hasConceptScore W1995652213C104317684 @default.

• next